Oncology drugs lead 2023 new medicines in Europe — EMA report

The Eu­ro­pean Med­i­cines Agency gave its stamp of ap­proval for 77 new drugs in 2023, with on­col­o­gy med­ica­tions lead­ing the pack with the most pos­i­tive opin­ions, the agency an­nounced in a re­port Tues­day.

The num­ber of over­all pos­i­tive rec­om­men­da­tions was slight­ly down from pre­vi­ous years, though the num­ber of new ac­tive in­gre­di­ents, 39, was on par with past years, EMA chief med­ical of­fi­cer Stef­fen Thirstrup said on a press call. Of the to­tal new drugs the EMA green­lit last year, on­col­o­gy led the pack with 25 new ap­provals, and neu­rol­o­gy and car­di­ol­o­gy drugs fol­lowed be­hind at 11 and six, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.